Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I2FI
|
|||
| Former ID |
DIB018049
|
|||
| Drug Name |
dequalinium
|
|||
| Synonyms |
dequalinium; Dequadin; 6707-58-0; UNII-E7QC7V26B8; Dequavagyn; Decamine; Labosept; Sorot; GNF-Pf-5483; E7QC7V26B8; CHEBI:41872; Polycidine; Dequavet; Dekadin; Rumilet; Dekamin; Sentril; Sanoral; Oralgol; Ivazil; Dequadin chloride; Dequalin chloride; C30H40N4; DEQ; 1,1'-decane-1,10-diylbis(4-amino-2-methylquinolinium); Solvidont; Quinolinium, 1,1'-(1,10-decanediyl)bis(4-amino-2-methyl-; 1-[10-(4-amino-2-methylquinolyl)decyl]-2-methyl-4-quinolylamine; CHEMBL121663
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Myelopathy [ICD-11: 8B42] | Clinical trial | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C30H40N4+2
|
|||
| Canonical SMILES |
CC1=[N+](C2=CC=CC=C2C(=C1)N)CCCCCCCCCC[N+]3=C(C=C(C4=CC=CC=C43)N)C
|
|||
| InChI |
1S/C30H38N4/c1-23-21-27(31)25-15-9-11-17-29(25)33(23)19-13-7-5-3-4-6-8-14-20-34-24(2)22-28(32)26-16-10-12-18-30(26)34/h9-12,15-18,21-22,31-32H,3-8,13-14,19-20H2,1-2H3/p+2
|
|||
| InChIKey |
PCSWXVJAIHCTMO-UHFFFAOYSA-P
|
|||
| CAS Number |
CAS 6707-58-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
794674, 823756, 5321553, 5321554, 7886971, 7980363, 8151905, 11111064, 11111065, 11113637, 11335927, 11361166, 11363045, 11365607, 11368169, 11374253, 11376331, 11405693, 11447327, 11462138, 11466416, 11467536, 11484395, 11486232, 11488466, 11492572, 11493965, 24262993, 29222142, 46507206, 47216801, 47216802, 47216803, 47365217, 47365218, 47810773, 47959772, 48185024, 48498627, 49698466, 50065046, 50104538, 50126458, 50126464, 56435827, 56435829, 57321546, 68533857, 76767627, 90340946
|
|||
| ChEBI ID |
CHEBI:41872
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Calcium-activated potassium channel KCa2.1 (KCNN1) | Target Info | Blocker (channel blocker) | [2] |
| Calcium-activated potassium channel KCa2.2 (KCNN2) | Target Info | Blocker (channel blocker) | [3] | |
| Calcium-activated potassium channel KCa2.3 (KCNN3) | Target Info | Blocker (channel blocker) | [1] | |
| Cyclic nucleotide-gated channel alpha-1 (CNGA1) | Target Info | Blocker (channel blocker) | [4] | |
| Cyclic nucleotide-gated channel alpha-2 (CNGA2) | Target Info | Blocker (channel blocker) | [5] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Pharmacological characterisation of the human small conductance calcium-activated potassium channel hSK3 reveals sensitivity to tricyclic antidepressants and antipsychotic phenothiazines. Neuropharmacology. 2001 May;40(6):772-83. | |||
| REF 2 | Pharmacological characterization of small-conductance Ca(2+)-activated K(+) channels stably expressed in HEK 293 cells. Br J Pharmacol. 2000 Mar;129(5):991-9. | |||
| REF 3 | Block of rat brain recombinant SK channels by tricyclic antidepressants and related compounds. Eur J Pharmacol. 2000 Jul 28;401(1):1-7. | |||
| REF 4 | Dequalinium: a novel, high-affinity blocker of CNGA1 channels. J Gen Physiol. 2003 Jan;121(1):37-47. | |||
| REF 5 | State-dependent block of CNG channels by dequalinium. J Gen Physiol. 2004 Mar;123(3):295-304. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.